nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—SLC6A2—locus ceruleus—Alzheimer's disease	0.0353	0.148	CbGeAlD
Phenylpropanolamine—MAOA—locus ceruleus—Alzheimer's disease	0.0325	0.136	CbGeAlD
Phenylpropanolamine—DRD1—telencephalic ventricle—Alzheimer's disease	0.0258	0.108	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.0207	0.0868	CbGeAlD
Phenylpropanolamine—Dysphoria—Donepezil—Alzheimer's disease	0.0182	0.049	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Memantine—Alzheimer's disease	0.00759	0.0205	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Rivastigmine—Alzheimer's disease	0.00742	0.02	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Memantine—Alzheimer's disease	0.00726	0.0196	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Rivastigmine—Alzheimer's disease	0.0071	0.0192	CcSEcCtD
Phenylpropanolamine—Urinary retention—Galantamine—Alzheimer's disease	0.00699	0.0189	CcSEcCtD
Phenylpropanolamine—Ataxia—Galantamine—Alzheimer's disease	0.00692	0.0187	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Donepezil—Alzheimer's disease	0.00675	0.0182	CcSEcCtD
Phenylpropanolamine—DRD1—forebrain—Alzheimer's disease	0.00674	0.0282	CbGeAlD
Phenylpropanolamine—DRD1—telencephalon—Alzheimer's disease	0.0062	0.0259	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Donepezil—Alzheimer's disease	0.00557	0.015	CcSEcCtD
Phenylpropanolamine—Irritability—Donepezil—Alzheimer's disease	0.00544	0.0147	CcSEcCtD
Phenylpropanolamine—Urinary retention—Donepezil—Alzheimer's disease	0.00542	0.0146	CcSEcCtD
Phenylpropanolamine—SLC6A3—forebrain—Alzheimer's disease	0.00542	0.0227	CbGeAlD
Phenylpropanolamine—Ataxia—Donepezil—Alzheimer's disease	0.00536	0.0145	CcSEcCtD
Phenylpropanolamine—ADRB1—forebrain—Alzheimer's disease	0.00514	0.0215	CbGeAlD
Phenylpropanolamine—Hallucination—Galantamine—Alzheimer's disease	0.00506	0.0137	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Memantine—Alzheimer's disease	0.00506	0.0136	CcSEcCtD
Phenylpropanolamine—SLC6A3—telencephalon—Alzheimer's disease	0.00498	0.0208	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Rivastigmine—Alzheimer's disease	0.00495	0.0134	CcSEcCtD
Phenylpropanolamine—Irritability—Memantine—Alzheimer's disease	0.00494	0.0133	CcSEcCtD
Phenylpropanolamine—Urinary retention—Memantine—Alzheimer's disease	0.00492	0.0133	CcSEcCtD
Phenylpropanolamine—Ataxia—Memantine—Alzheimer's disease	0.00487	0.0131	CcSEcCtD
Phenylpropanolamine—Urinary retention—Rivastigmine—Alzheimer's disease	0.00482	0.013	CcSEcCtD
Phenylpropanolamine—Ataxia—Rivastigmine—Alzheimer's disease	0.00476	0.0129	CcSEcCtD
Phenylpropanolamine—ADRB1—telencephalon—Alzheimer's disease	0.00472	0.0198	CbGeAlD
Phenylpropanolamine—Flushing—Galantamine—Alzheimer's disease	0.00472	0.0128	CcSEcCtD
Phenylpropanolamine—MAOA—embryo—Alzheimer's disease	0.00455	0.019	CbGeAlD
Phenylpropanolamine—Arrhythmia—Galantamine—Alzheimer's disease	0.00455	0.0123	CcSEcCtD
Phenylpropanolamine—SLC6A2—forebrain—Alzheimer's disease	0.00437	0.0183	CbGeAlD
Phenylpropanolamine—Tension—Galantamine—Alzheimer's disease	0.00435	0.0117	CcSEcCtD
Phenylpropanolamine—Nervousness—Galantamine—Alzheimer's disease	0.0043	0.0116	CcSEcCtD
Phenylpropanolamine—Vision blurred—Galantamine—Alzheimer's disease	0.00418	0.0113	CcSEcCtD
Phenylpropanolamine—Tremor—Galantamine—Alzheimer's disease	0.00415	0.0112	CcSEcCtD
Phenylpropanolamine—Agitation—Galantamine—Alzheimer's disease	0.00407	0.011	CcSEcCtD
Phenylpropanolamine—ADRA1A—forebrain—Alzheimer's disease	0.00406	0.017	CbGeAlD
Phenylpropanolamine—MAOA—forebrain—Alzheimer's disease	0.00403	0.0168	CbGeAlD
Phenylpropanolamine—SLC6A2—telencephalon—Alzheimer's disease	0.00402	0.0168	CbGeAlD
Phenylpropanolamine—Hallucination—Donepezil—Alzheimer's disease	0.00392	0.0106	CcSEcCtD
Phenylpropanolamine—Drowsiness—Rivastigmine—Alzheimer's disease	0.0039	0.0105	CcSEcCtD
Phenylpropanolamine—Anxiety—Galantamine—Alzheimer's disease	0.00376	0.0101	CcSEcCtD
Phenylpropanolamine—ADRA1A—telencephalon—Alzheimer's disease	0.00374	0.0156	CbGeAlD
Phenylpropanolamine—MAOA—telencephalon—Alzheimer's disease	0.0037	0.0155	CbGeAlD
Phenylpropanolamine—DRD1—nervous system—Alzheimer's disease	0.00366	0.0153	CbGeAlD
Phenylpropanolamine—Confusional state—Galantamine—Alzheimer's disease	0.00365	0.00984	CcSEcCtD
Phenylpropanolamine—Hallucination—Memantine—Alzheimer's disease	0.00356	0.00962	CcSEcCtD
Phenylpropanolamine—Tachycardia—Galantamine—Alzheimer's disease	0.00353	0.00953	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Donepezil—Alzheimer's disease	0.00352	0.00951	CcSEcCtD
Phenylpropanolamine—DRD1—central nervous system—Alzheimer's disease	0.00352	0.0147	CbGeAlD
Phenylpropanolamine—Hallucination—Rivastigmine—Alzheimer's disease	0.00349	0.00941	CcSEcCtD
Phenylpropanolamine—Hypotension—Galantamine—Alzheimer's disease	0.00338	0.00912	CcSEcCtD
Phenylpropanolamine—Tension—Donepezil—Alzheimer's disease	0.00337	0.0091	CcSEcCtD
Phenylpropanolamine—Nervousness—Donepezil—Alzheimer's disease	0.00333	0.009	CcSEcCtD
Phenylpropanolamine—Flushing—Memantine—Alzheimer's disease	0.00332	0.00897	CcSEcCtD
Phenylpropanolamine—Insomnia—Galantamine—Alzheimer's disease	0.00327	0.00883	CcSEcCtD
Phenylpropanolamine—Flushing—Rivastigmine—Alzheimer's disease	0.00325	0.00878	CcSEcCtD
Phenylpropanolamine—Vision blurred—Donepezil—Alzheimer's disease	0.00324	0.00873	CcSEcCtD
Phenylpropanolamine—Tremor—Donepezil—Alzheimer's disease	0.00322	0.00868	CcSEcCtD
Phenylpropanolamine—Somnolence—Galantamine—Alzheimer's disease	0.00321	0.00868	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Memantine—Alzheimer's disease	0.0032	0.00864	CcSEcCtD
Phenylpropanolamine—Agitation—Donepezil—Alzheimer's disease	0.00316	0.00852	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Rivastigmine—Alzheimer's disease	0.00313	0.00845	CcSEcCtD
Phenylpropanolamine—Constipation—Galantamine—Alzheimer's disease	0.00309	0.00835	CcSEcCtD
Phenylpropanolamine—ADRA2A—forebrain—Alzheimer's disease	0.00309	0.0129	CbGeAlD
Phenylpropanolamine—Tension—Memantine—Alzheimer's disease	0.00306	0.00826	CcSEcCtD
Phenylpropanolamine—Nervousness—Memantine—Alzheimer's disease	0.00303	0.00817	CcSEcCtD
Phenylpropanolamine—Tension—Rivastigmine—Alzheimer's disease	0.00299	0.00808	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Galantamine—Alzheimer's disease	0.00298	0.00804	CcSEcCtD
Phenylpropanolamine—Nervousness—Rivastigmine—Alzheimer's disease	0.00296	0.008	CcSEcCtD
Phenylpropanolamine—SLC6A3—nervous system—Alzheimer's disease	0.00294	0.0123	CbGeAlD
Phenylpropanolamine—Vision blurred—Memantine—Alzheimer's disease	0.00294	0.00793	CcSEcCtD
Phenylpropanolamine—Tremor—Memantine—Alzheimer's disease	0.00292	0.00788	CcSEcCtD
Phenylpropanolamine—Anxiety—Donepezil—Alzheimer's disease	0.00291	0.00786	CcSEcCtD
Phenylpropanolamine—Vision blurred—Rivastigmine—Alzheimer's disease	0.00287	0.00776	CcSEcCtD
Phenylpropanolamine—Agitation—Memantine—Alzheimer's disease	0.00286	0.00773	CcSEcCtD
Phenylpropanolamine—Tremor—Rivastigmine—Alzheimer's disease	0.00286	0.00771	CcSEcCtD
Phenylpropanolamine—ADRA2A—telencephalon—Alzheimer's disease	0.00284	0.0119	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—Alzheimer's disease	0.00283	0.0118	CbGeAlD
Phenylpropanolamine—Confusional state—Donepezil—Alzheimer's disease	0.00283	0.00763	CcSEcCtD
Phenylpropanolamine—Agitation—Rivastigmine—Alzheimer's disease	0.0028	0.00757	CcSEcCtD
Phenylpropanolamine—DRD1—brain—Alzheimer's disease	0.0028	0.0117	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—Alzheimer's disease	0.00279	0.0117	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—Alzheimer's disease	0.00277	0.0116	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—Alzheimer's disease	0.00269	0.0112	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Galantamine—Alzheimer's disease	0.00266	0.00719	CcSEcCtD
Phenylpropanolamine—Anxiety—Memantine—Alzheimer's disease	0.00264	0.00714	CcSEcCtD
Phenylpropanolamine—Hypotension—Donepezil—Alzheimer's disease	0.00262	0.00707	CcSEcCtD
Phenylpropanolamine—Anxiety—Rivastigmine—Alzheimer's disease	0.00259	0.00698	CcSEcCtD
Phenylpropanolamine—Confusional state—Memantine—Alzheimer's disease	0.00257	0.00693	CcSEcCtD
Phenylpropanolamine—Insomnia—Donepezil—Alzheimer's disease	0.00253	0.00684	CcSEcCtD
Phenylpropanolamine—Confusional state—Rivastigmine—Alzheimer's disease	0.00251	0.00677	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Donepezil—Alzheimer's disease	0.0025	0.00674	CcSEcCtD
Phenylpropanolamine—Somnolence—Donepezil—Alzheimer's disease	0.00249	0.00672	CcSEcCtD
Phenylpropanolamine—Tachycardia—Memantine—Alzheimer's disease	0.00248	0.0067	CcSEcCtD
Phenylpropanolamine—Tachycardia—Rivastigmine—Alzheimer's disease	0.00243	0.00656	CcSEcCtD
Phenylpropanolamine—Ephedrine—ACHE—Alzheimer's disease	0.00241	0.116	CrCbGaD
Phenylpropanolamine—Constipation—Donepezil—Alzheimer's disease	0.0024	0.00647	CcSEcCtD
Phenylpropanolamine—Dizziness—Galantamine—Alzheimer's disease	0.00239	0.00645	CcSEcCtD
Phenylpropanolamine—Hypotension—Memantine—Alzheimer's disease	0.00238	0.00642	CcSEcCtD
Phenylpropanolamine—SLC6A2—nervous system—Alzheimer's disease	0.00237	0.00992	CbGeAlD
Phenylpropanolamine—Tranylcypromine—MAOB—Alzheimer's disease	0.00233	0.113	CrCbGaD
Phenylpropanolamine—Hypotension—Rivastigmine—Alzheimer's disease	0.00233	0.00628	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Donepezil—Alzheimer's disease	0.00231	0.00623	CcSEcCtD
Phenylpropanolamine—Insomnia—Memantine—Alzheimer's disease	0.0023	0.00621	CcSEcCtD
Phenylpropanolamine—Vomiting—Galantamine—Alzheimer's disease	0.0023	0.00621	CcSEcCtD
Phenylpropanolamine—SLC6A2—central nervous system—Alzheimer's disease	0.00228	0.00955	CbGeAlD
Phenylpropanolamine—Rash—Galantamine—Alzheimer's disease	0.00228	0.00615	CcSEcCtD
Phenylpropanolamine—Dermatitis—Galantamine—Alzheimer's disease	0.00228	0.00615	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Memantine—Alzheimer's disease	0.00227	0.00612	CcSEcCtD
Phenylpropanolamine—Somnolence—Memantine—Alzheimer's disease	0.00226	0.00611	CcSEcCtD
Phenylpropanolamine—Insomnia—Rivastigmine—Alzheimer's disease	0.00225	0.00608	CcSEcCtD
Phenylpropanolamine—SLC6A3—brain—Alzheimer's disease	0.00225	0.0094	CbGeAlD
Phenylpropanolamine—Dyspnoea—Rivastigmine—Alzheimer's disease	0.00222	0.00599	CcSEcCtD
Phenylpropanolamine—Somnolence—Rivastigmine—Alzheimer's disease	0.00221	0.00597	CcSEcCtD
Phenylpropanolamine—ADRA1A—nervous system—Alzheimer's disease	0.00221	0.00923	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—Alzheimer's disease	0.00219	0.00914	CbGeAlD
Phenylpropanolamine—Constipation—Memantine—Alzheimer's disease	0.00218	0.00587	CcSEcCtD
Phenylpropanolamine—Nausea—Galantamine—Alzheimer's disease	0.00215	0.0058	CcSEcCtD
Phenylpropanolamine—ADRB1—brain—Alzheimer's disease	0.00213	0.00892	CbGeAlD
Phenylpropanolamine—Constipation—Rivastigmine—Alzheimer's disease	0.00213	0.00575	CcSEcCtD
Phenylpropanolamine—ADRA1A—central nervous system—Alzheimer's disease	0.00212	0.00888	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—Alzheimer's disease	0.0021	0.0088	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Memantine—Alzheimer's disease	0.0021	0.00566	CcSEcCtD
Phenylpropanolamine—ADRA1A—cerebellum—Alzheimer's disease	0.00208	0.00868	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Donepezil—Alzheimer's disease	0.00206	0.00557	CcSEcCtD
Phenylpropanolamine—MAOA—cerebellum—Alzheimer's disease	0.00206	0.0086	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.00205	0.00554	CcSEcCtD
Phenylpropanolamine—Phentermine—MAOB—Alzheimer's disease	0.00196	0.0943	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Memantine—Alzheimer's disease	0.00187	0.00506	CcSEcCtD
Phenylpropanolamine—Dizziness—Donepezil—Alzheimer's disease	0.00185	0.005	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.00183	0.00495	CcSEcCtD
Phenylpropanolamine—SLC6A2—brain—Alzheimer's disease	0.00181	0.00759	CbGeAlD
Phenylpropanolamine—Vomiting—Donepezil—Alzheimer's disease	0.00178	0.00481	CcSEcCtD
Phenylpropanolamine—Rash—Donepezil—Alzheimer's disease	0.00177	0.00477	CcSEcCtD
Phenylpropanolamine—Dermatitis—Donepezil—Alzheimer's disease	0.00177	0.00477	CcSEcCtD
Phenylpropanolamine—ADRA1A—brain—Alzheimer's disease	0.00169	0.00705	CbGeAlD
Phenylpropanolamine—Dizziness—Memantine—Alzheimer's disease	0.00168	0.00454	CcSEcCtD
Phenylpropanolamine—ADRA2A—nervous system—Alzheimer's disease	0.00168	0.00702	CbGeAlD
Phenylpropanolamine—MAOA—brain—Alzheimer's disease	0.00167	0.00699	CbGeAlD
Phenylpropanolamine—Nausea—Donepezil—Alzheimer's disease	0.00166	0.00449	CcSEcCtD
Phenylpropanolamine—Dizziness—Rivastigmine—Alzheimer's disease	0.00165	0.00444	CcSEcCtD
Phenylpropanolamine—Vomiting—Memantine—Alzheimer's disease	0.00162	0.00437	CcSEcCtD
Phenylpropanolamine—ADRA2A—central nervous system—Alzheimer's disease	0.00161	0.00675	CbGeAlD
Phenylpropanolamine—Rash—Memantine—Alzheimer's disease	0.0016	0.00433	CcSEcCtD
Phenylpropanolamine—Dermatitis—Memantine—Alzheimer's disease	0.0016	0.00433	CcSEcCtD
Phenylpropanolamine—Phenelzine—MAOB—Alzheimer's disease	0.00159	0.0769	CrCbGaD
Phenylpropanolamine—Vomiting—Rivastigmine—Alzheimer's disease	0.00158	0.00427	CcSEcCtD
Phenylpropanolamine—ADRA2A—cerebellum—Alzheimer's disease	0.00158	0.0066	CbGeAlD
Phenylpropanolamine—Rash—Rivastigmine—Alzheimer's disease	0.00157	0.00424	CcSEcCtD
Phenylpropanolamine—Dermatitis—Rivastigmine—Alzheimer's disease	0.00157	0.00423	CcSEcCtD
Phenylpropanolamine—Nausea—Memantine—Alzheimer's disease	0.00151	0.00408	CcSEcCtD
Phenylpropanolamine—Amphetamine—MAOB—Alzheimer's disease	0.0015	0.0725	CrCbGaD
Phenylpropanolamine—Nausea—Rivastigmine—Alzheimer's disease	0.00148	0.00399	CcSEcCtD
Phenylpropanolamine—Ephedrine—BCHE—Alzheimer's disease	0.00142	0.0683	CrCbGaD
Phenylpropanolamine—Methamphetamine—MAOB—Alzheimer's disease	0.00139	0.0672	CrCbGaD
Phenylpropanolamine—ADRA2A—brain—Alzheimer's disease	0.00128	0.00536	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—TNF—Alzheimer's disease	0.00104	0.0502	CrCbGaD
Phenylpropanolamine—Phentermine—SLC6A4—Alzheimer's disease	0.000884	0.0426	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—Alzheimer's disease	0.000838	0.0404	CrCbGaD
Phenylpropanolamine—Tranylcypromine—CYP2D6—Alzheimer's disease	0.000741	0.0357	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A4—Alzheimer's disease	0.00068	0.0328	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A4—Alzheimer's disease	0.00063	0.0304	CrCbGaD
Phenylpropanolamine—Phentermine—CYP2D6—Alzheimer's disease	0.000621	0.03	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP2D6—Alzheimer's disease	0.000599	0.0289	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—CYP2D6—Alzheimer's disease	0.000593	0.0286	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—CYP2D6—Alzheimer's disease	0.000589	0.0284	CrCbGaD
Phenylpropanolamine—Amphetamine—CYP2D6—Alzheimer's disease	0.000478	0.023	CrCbGaD
Phenylpropanolamine—Methamphetamine—CYP2D6—Alzheimer's disease	0.000443	0.0213	CrCbGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CREB1—Alzheimer's disease	4.7e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—F2—Alzheimer's disease	4.7e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTK2B—Alzheimer's disease	4.69e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CRH—Alzheimer's disease	4.68e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLCB1—Alzheimer's disease	4.66e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCR5—Alzheimer's disease	4.62e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADAM10—Alzheimer's disease	4.62e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CCL2—Alzheimer's disease	4.6e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1R—Alzheimer's disease	4.57e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GAB2—Alzheimer's disease	4.56e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SST—Alzheimer's disease	4.56e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTRK2—Alzheimer's disease	4.56e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CALM1—Alzheimer's disease	4.54e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—Alzheimer's disease	4.52e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GSK3A—Alzheimer's disease	4.52e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCA1—Alzheimer's disease	4.52e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—S100B—Alzheimer's disease	4.47e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CALM1—Alzheimer's disease	4.46e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—Alzheimer's disease	4.45e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APP—Alzheimer's disease	4.44e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NPS—Alzheimer's disease	4.44e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PPP3CA—Alzheimer's disease	4.42e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CAV1—Alzheimer's disease	4.41e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	4.39e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—LPL—Alzheimer's disease	4.38e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—S100B—Alzheimer's disease	4.37e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—F2—Alzheimer's disease	4.37e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTK2B—Alzheimer's disease	4.36e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MEF2C—Alzheimer's disease	4.35e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—F2—Alzheimer's disease	4.27e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRKCG—Alzheimer's disease	4.26e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF2—Alzheimer's disease	4.25e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GAB2—Alzheimer's disease	4.24e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTRK2—Alzheimer's disease	4.24e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SST—Alzheimer's disease	4.24e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CALM1—Alzheimer's disease	4.22e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GSK3A—Alzheimer's disease	4.2e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLCB1—Alzheimer's disease	4.19e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF2—Alzheimer's disease	4.16e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NGF—Alzheimer's disease	4.15e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APP—Alzheimer's disease	4.13e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1R—Alzheimer's disease	4.11e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCR5—Alzheimer's disease	4.04e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPI1—Alzheimer's disease	4.04e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CHAT—Alzheimer's disease	4.04e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1R—Alzheimer's disease	4.02e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—F2—Alzheimer's disease	3.97e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—Alzheimer's disease	3.95e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—Alzheimer's disease	3.95e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LPL—Alzheimer's disease	3.94e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NGFR—Alzheimer's disease	3.91e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MEF2C—Alzheimer's disease	3.91e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLCB1—Alzheimer's disease	3.9e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARGC1A—Alzheimer's disease	3.89e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CREB1—Alzheimer's disease	3.89e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HMOX1—Alzheimer's disease	3.87e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PPARG—Alzheimer's disease	3.87e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOB—Alzheimer's disease	3.87e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LPL—Alzheimer's disease	3.86e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKCG—Alzheimer's disease	3.83e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MEF2C—Alzheimer's disease	3.82e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADAM10—Alzheimer's disease	3.82e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCL2—Alzheimer's disease	3.8e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—INS—Alzheimer's disease	3.8e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKCG—Alzheimer's disease	3.75e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NGF—Alzheimer's disease	3.73e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	3.72e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CALM1—Alzheimer's disease	3.69e-05	9.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	3.68e-05	9.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—Alzheimer's disease	3.68e-05	9.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—LEP—Alzheimer's disease	3.68e-05	9.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NGF—Alzheimer's disease	3.65e-05	9.88e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	3.65e-05	9.87e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CAV1—Alzheimer's disease	3.64e-05	9.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NGFR—Alzheimer's disease	3.64e-05	9.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCR5—Alzheimer's disease	3.63e-05	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—Alzheimer's disease	3.63e-05	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—S100B—Alzheimer's disease	3.61e-05	9.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CREB1—Alzheimer's disease	3.61e-05	9.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—A2M—Alzheimer's disease	3.6e-05	9.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—Alzheimer's disease	3.55e-05	9.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCR5—Alzheimer's disease	3.55e-05	9.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADAM10—Alzheimer's disease	3.55e-05	9.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—LPL—Alzheimer's disease	3.54e-05	9.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL2—Alzheimer's disease	3.53e-05	9.56e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ESR1—Alzheimer's disease	3.51e-05	9.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—Alzheimer's disease	3.48e-05	9.4e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—F2—Alzheimer's disease	3.47e-05	9.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF2—Alzheimer's disease	3.44e-05	9.3e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOTCH1—Alzheimer's disease	3.39e-05	9.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—S100B—Alzheimer's disease	3.36e-05	9.08e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NOS3—Alzheimer's disease	3.33e-05	9.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1R—Alzheimer's disease	3.33e-05	9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CALM1—Alzheimer's disease	3.32e-05	8.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LEP—Alzheimer's disease	3.3e-05	8.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—Alzheimer's disease	3.3e-05	8.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CAV1—Alzheimer's disease	3.27e-05	8.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CALM1—Alzheimer's disease	3.24e-05	8.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—Alzheimer's disease	3.23e-05	8.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LEP—Alzheimer's disease	3.23e-05	8.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	3.21e-05	8.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CAV1—Alzheimer's disease	3.2e-05	8.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF2—Alzheimer's disease	3.2e-05	8.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—Alzheimer's disease	3.19e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LPL—Alzheimer's disease	3.19e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GSK3B—Alzheimer's disease	3.18e-05	8.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MEF2C—Alzheimer's disease	3.16e-05	8.55e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CREB1—Alzheimer's disease	3.16e-05	8.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ESR1—Alzheimer's disease	3.15e-05	8.53e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—INS—Alzheimer's disease	3.14e-05	8.49e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ACHE—Alzheimer's disease	3.13e-05	8.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—F2—Alzheimer's disease	3.12e-05	8.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCG—Alzheimer's disease	3.1e-05	8.39e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	3.09e-05	8.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1R—Alzheimer's disease	3.09e-05	8.36e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—Alzheimer's disease	3.09e-05	8.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—Alzheimer's disease	3.09e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOTCH1—Alzheimer's disease	3.05e-05	8.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—F2—Alzheimer's disease	3.05e-05	8.24e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—Alzheimer's disease	3.05e-05	8.24e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—Alzheimer's disease	3.04e-05	8.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NGF—Alzheimer's disease	3.02e-05	8.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—Alzheimer's disease	2.99e-05	8.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOTCH1—Alzheimer's disease	2.98e-05	8.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CALM1—Alzheimer's disease	2.98e-05	8.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—Alzheimer's disease	2.97e-05	8.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LPL—Alzheimer's disease	2.96e-05	8.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CAV1—Alzheimer's disease	2.94e-05	7.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR5—Alzheimer's disease	2.94e-05	7.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MEF2C—Alzheimer's disease	2.94e-05	7.94e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	2.93e-05	7.93e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ENO1—Alzheimer's disease	2.93e-05	7.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCG—Alzheimer's disease	2.88e-05	7.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—Alzheimer's disease	2.88e-05	7.78e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	2.88e-05	7.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GSK3B—Alzheimer's disease	2.86e-05	7.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CREB1—Alzheimer's disease	2.84e-05	7.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INS—Alzheimer's disease	2.82e-05	7.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NGF—Alzheimer's disease	2.81e-05	7.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GSK3B—Alzheimer's disease	2.8e-05	7.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—Alzheimer's disease	2.78e-05	7.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CREB1—Alzheimer's disease	2.78e-05	7.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INS—Alzheimer's disease	2.76e-05	7.47e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOS3—Alzheimer's disease	2.75e-05	7.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR5—Alzheimer's disease	2.73e-05	7.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—Alzheimer's disease	2.73e-05	7.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—Alzheimer's disease	2.73e-05	7.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—Alzheimer's disease	2.72e-05	7.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CALM1—Alzheimer's disease	2.68e-05	7.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—Alzheimer's disease	2.67e-05	7.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—Alzheimer's disease	2.67e-05	7.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—Alzheimer's disease	2.67e-05	7.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—Alzheimer's disease	2.67e-05	7.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CAV1—Alzheimer's disease	2.65e-05	7.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—Alzheimer's disease	2.59e-05	7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	2.57e-05	6.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—Alzheimer's disease	2.55e-05	6.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—Alzheimer's disease	2.54e-05	6.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—Alzheimer's disease	2.52e-05	6.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	2.52e-05	6.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—F2—Alzheimer's disease	2.52e-05	6.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	2.49e-05	6.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CALM1—Alzheimer's disease	2.49e-05	6.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—Alzheimer's disease	2.48e-05	6.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—Alzheimer's disease	2.48e-05	6.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—Alzheimer's disease	2.48e-05	6.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH1—Alzheimer's disease	2.47e-05	6.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—Alzheimer's disease	2.46e-05	6.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—Alzheimer's disease	2.42e-05	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—Alzheimer's disease	2.37e-05	6.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—Alzheimer's disease	2.36e-05	6.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—F2—Alzheimer's disease	2.34e-05	6.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—Alzheimer's disease	2.34e-05	6.32e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—Alzheimer's disease	2.32e-05	6.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GSK3B—Alzheimer's disease	2.32e-05	6.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CREB1—Alzheimer's disease	2.3e-05	6.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH1—Alzheimer's disease	2.29e-05	6.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—Alzheimer's disease	2.28e-05	6.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—Alzheimer's disease	2.25e-05	6.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—Alzheimer's disease	2.23e-05	6.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—Alzheimer's disease	2.21e-05	5.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GSK3B—Alzheimer's disease	2.15e-05	5.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	2.15e-05	5.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—Alzheimer's disease	2.15e-05	5.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—Alzheimer's disease	2.14e-05	5.79e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	2.14e-05	5.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CREB1—Alzheimer's disease	2.13e-05	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—Alzheimer's disease	2.12e-05	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—Alzheimer's disease	2.12e-05	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—Alzheimer's disease	2.1e-05	5.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—Alzheimer's disease	2.09e-05	5.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—Alzheimer's disease	2.09e-05	5.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—Alzheimer's disease	2.07e-05	5.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—Alzheimer's disease	2.06e-05	5.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—Alzheimer's disease	2.05e-05	5.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—Alzheimer's disease	2.04e-05	5.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—Alzheimer's disease	2.04e-05	5.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—Alzheimer's disease	2e-05	5.42e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—Alzheimer's disease	1.98e-05	5.36e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LPL—Alzheimer's disease	1.96e-05	5.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—Alzheimer's disease	1.93e-05	5.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—Alzheimer's disease	1.93e-05	5.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—Alzheimer's disease	1.89e-05	5.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—Alzheimer's disease	1.88e-05	5.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—Alzheimer's disease	1.86e-05	5.03e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—Alzheimer's disease	1.82e-05	4.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—Alzheimer's disease	1.78e-05	4.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	1.76e-05	4.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—Alzheimer's disease	1.74e-05	4.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—Alzheimer's disease	1.72e-05	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—Alzheimer's disease	1.7e-05	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—Alzheimer's disease	1.69e-05	4.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CALM1—Alzheimer's disease	1.65e-05	4.45e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—Alzheimer's disease	1.64e-05	4.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—Alzheimer's disease	1.64e-05	4.43e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—Alzheimer's disease	1.62e-05	4.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—Alzheimer's disease	1.6e-05	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—Alzheimer's disease	1.59e-05	4.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—Alzheimer's disease	1.58e-05	4.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—Alzheimer's disease	1.57e-05	4.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—Alzheimer's disease	1.56e-05	4.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—Alzheimer's disease	1.56e-05	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—Alzheimer's disease	1.53e-05	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—Alzheimer's disease	1.5e-05	4.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—Alzheimer's disease	1.45e-05	3.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—Alzheimer's disease	1.45e-05	3.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—Alzheimer's disease	1.44e-05	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—Alzheimer's disease	1.43e-05	3.86e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—Alzheimer's disease	1.4e-05	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—Alzheimer's disease	1.37e-05	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—Alzheimer's disease	1.35e-05	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—Alzheimer's disease	1.34e-05	3.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—Alzheimer's disease	1.32e-05	3.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—Alzheimer's disease	1.32e-05	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—Alzheimer's disease	1.27e-05	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—Alzheimer's disease	1.23e-05	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.23e-05	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—Alzheimer's disease	1.23e-05	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—Alzheimer's disease	1.21e-05	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—Alzheimer's disease	1.14e-05	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	1.12e-05	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—Alzheimer's disease	1.11e-05	3.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—Alzheimer's disease	1.09e-05	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—Alzheimer's disease	1.02e-05	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—Alzheimer's disease	1.01e-05	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—Alzheimer's disease	9.98e-06	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—Alzheimer's disease	9.27e-06	2.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—Alzheimer's disease	9.21e-06	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—Alzheimer's disease	8.55e-06	2.31e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—Alzheimer's disease	5.65e-06	1.53e-05	CbGpPWpGaD
